In Europe, revised rules for the Clinical Trials Information System (CTIS) are now applicable, offering faster access to clinical trial information.
CTIS serves as the single-entry point for the submission and assessment of clinical trial applications in the European Union.
European regulators have introduced certain changes, with the goal of benefiting patients, healthcare professionals, and other stakeholders by providing earlier and more efficient access to clinical trial data.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze